DeepMatter Group Plc (AIM: DMTR, “DeepMatter”, the “Group”), the international digital chemistry data company, has created a new Scientific Advisory Board (“SAB”) to be led by Professor Richard Bourne, who was recently promoted to Professor at the University of Leeds and appointed Research Chair of Royal Academy of Engineering. The SAB, which is made up […]
DeepMatter Group Plc (AIM: DMTR, “DeepMatter”, the “Group”), the international digital chemistry data company, has signed a contract with Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), based in Hyderabad, India, for its DigitalGlassware® platform. DeepMatter will provide its DigitalGlassware® platform to Dr Reddy’s process development team who are looking to the development and scale up of chemistry procedures to […]
Appointment brings extensive pharmaceutical services and Board experience to drive commercial growth and development of new products to improve speed, efficiency, and productivity of drug discovery CAMBRIDGE, UK: Optibrium™, a developer of software for drug discovery, today announced the appointment of Professor Andy Black as non-executive Chair of its Board of Directors. Following the company’s recent […]
Cambridge, UK – 14 September 2021 – Cresset Discovery Services, provider of contract research services for early phase of drug discovery, has announced it will collaborate with the University of Newcastle, Australia, to focus on drug reprofiling against oncology targets. The work will build on research led by award-winning molecular biologist, Associate Professor Nikola Bowden. Nikola is […]
SANTA FE, N.M., USA, & KYIV, Ukraine – OpenEye Scientific and Enamine, a leading global provider of billions of new screening compounds to the drug discovery market, are partnering to enable faster and more accurate virtual screening of ultra-large compound libraries through access to innovative software. Using Orion®, OpenEye’s cloud-native molecular design platform, scientists can: […]
Innovative predictive methods support virtual screening and compound design in the absence of 3D structure data CAMBRIDGE, UK: Optibrium Ltd, a developer of software for drug discovery, today announced the release of the latest version of StarDrop™, its comprehensive software platform for small molecule design, optimisation and data analysis. StarDrop is used by more than 160 […]
DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, has commenced a project with the University of Cambridge’s Innovation Centre in Digital Molecular Technologies (iDMT), an open innovation research centre co-funded by the University of Cambridge, AstraZeneca, Shionogi, and the European Regional Development Fund. DeepMatter will provide its DigitalGlassware® platform to iDMT as part of the […]
Cambridge, UK – 21 July 2021 – Cresset, innovative provider of outstanding software for molecule discovery and design, is pleased to announce that OncoArendi Therapeutics SA (WSE: OAT), a biotechnology company which specializes in the discovery and development of new drugs, has licensed Flare™ for use in its internal development programs. Cresset software uses its proprietary descriptors of […]
DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, is pleased to announce that Bryn Roberts has been appointed to the Board as Non-Executive Director with effect from 1 August 2021. Bryn brings a wealth of experience in the pharmaceutical sector having spent 15 years at Roche, the Swiss multinational healthcare company. He is […]
I am delighted to announce that Flare™ V5 is now available. This release of Cresset’s comprehensive platform for drug design features new and enhanced science, integration of ligand- and protein-based approaches and new and improved GUI features to increase usability. Cutting edge QSAR methods With this release, Flare has evolved from a structure-based solution into a comprehensive drug […]
Pay Invoice
Latest Blogs
-
MOBILion Expands into Proteomics MS Market
April 30, 2026 5:05 pm
-
Carterra Introduces Faster SPR
March 27, 2026 7:26 pm
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
